Anemia Drugs Market

Global Anemia Drugs Market Research Report Global Industry Analysis, Size, Share, Growth, Trends, Regional Analysis, Competitor Analysis and Forecast 2024-2032: By Anemia Type (Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Others), By Route of Administration (Oral and Injectable), and Region (North America, Europe, Asia-Pacific, and Rest of the World)

Pharma & Healthcare | March 2024 | Report ID: EMR00663 | Pages: 250

The global anemia drugs market was valued at USD 14.76 billion in 2023 and is estimated to reach approximately USD 33.25 billion by 2032, at a CAGR of 9.4% from 2024 to 2032.

The market for anemia medications has expanded significantly as a result of the growing incidence of anemia around the world, especially in emerging nations. Low amounts of hemoglobin or red blood cells cause anemia, which can cause symptoms including weakness and exhaustion that must be effectively treated. The treatment of anemia has changed dramatically with the introduction of novel medications, such as iron supplements and erythropoietin-stimulating agents (ESAs). These medications treat a number of underlying causes of anemia, including iron deficiency, chronic renal disease, and anemia linked to cancer, by increasing the generation of red blood cells or replenishing iron storage. The market for anemia medications is expected to grow steadily due to rising awareness, improvements in healthcare infrastructure, and advances in research.



Report Attribute


Estimated Market Value (2023)

14.76 Bn

Projected Market Value (2032)

33.25 Bn

Base Year


Forecast Years

2024 - 2032

Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- By Anemia Type, By Route of Administration, & Region

Segments Covered

By Anemia Type, By Route of Administration, & Region

Forecast Units

Value (USD Billion or Million), and Volume (Units)

Quantitative Units

Revenue in USD million/billion and CAGR from 2024 to 2032

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and the Rest of World

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others

Report Coverage

Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.

Delivery Format

Delivered as an attached PDF and Excel through email, according to the purchase option.


Global Anemia Drugs Dynamics

The market for anemia medications is fueled by factors including the rising incidence of anemia, particularly in developing nations, and the arrival of innovative treatments. The growing elderly population, who are more vulnerable to anemia because of age-related issues, has an impact on the market as well. Additionally, the market is growing due to improvements in the healthcare infrastructure and rising awareness of anemia treatment alternatives. However, obstacles including the high cost of care, particularly in poorer nations, and the availability of substitute medicines such as blood transfusions are impeding market growth.


Global Anemia Drugs Drivers

  • Increasing Prevalence of Anemia

The market for anemia medications is mostly driven by the rising incidence of anemia, especially in emerging nations. This trend is influenced by elements including poor diet, chronic illnesses, and limited access to healthcare. The need for efficient anemia therapies is further increased by demographic changes, such as aging populations. Due to the increasing prevalence of anemia, there is a pressing need for novel medications and treatments to address its various causes, which is propelling the expansion of the pharmacological intervention market.

  • Advancements in Healthcare Infrastructure

Timely detection and management of anemia is made easier by improved healthcare infrastructure, such as increased distribution networks, specialized treatment centers, and better diagnostic capabilities. The use of new anemia medications is encouraged by access to cutting-edge medical treatments and technologies as well as higher healthcare spending. Opportunities to grow their market share and provide cutting-edge anemia management solutions present themselves for pharmaceutical businesses as healthcare systems adapt to meet the rising demand for high-quality care.



  • High Treatment Costs

For patients, the costs of obtaining and administering anemia treatments can be exorbitant, especially in areas where access to healthcare is limited or insurance coverage is insufficient. Expensive treatments may also put a strain on healthcare budgets and restrict alternatives for reimbursement, which would lower patient accessibility and affordability. This cost barrier prevents anemia medications from being widely used, which restricts market expansion and exacerbates gaps in healthcare outcomes and access.

  • Safety Concerns and Side Effects

Certain anemia drugs may have unfavorable side effects, such as thrombotic problems and cardiovascular events, even when they are effective. These safety concerns may result in increased vigilance from prescribers and patients, market withdrawals, or regulatory investigation. Fears of possible danger would discourage people from starting or continuing their therapy, which would undermine market demand and erode trust in anemia medication solutions, preventing the market's growth and uptake.



  • Expanding Geriatric Population

Anemia is more common as people age because of things like chronic illnesses and a decline in red blood cell formation. Effective anemia treatments are in higher demand as the number of elderly people rises since they can enhance quality of life and lower problems. Pharmaceutical companies can benefit from this demographic trend by creating customized treatments and focused interventions that cater to the special requirements of elderly individuals suffering from anemia, hence propelling the market's expansion.

  • Technological Advancements in Drug Development

Novel approaches including biotechnology, computer modeling, and high-throughput screening enable the quick identification and improvement of new therapeutic options. Furthermore, improvements in drug delivery technologies improve the safety and effectiveness of anemia treatments, leading to better patient results and satisfaction. Pharmaceutical businesses can extend their market presence and meet unmet medical needs by developing more potent, focused, and affordable anemic medicines by utilizing these creative ways.


Segment Overview

  • By Anemia Type

Based on anemia type, the global anemia drugs market is divided into iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia, pernicious anemia and others. The iron deficiency anemia category dominates the market with the largest revenue share in 2023. This kind of anemia, which is brought on by low iron levels in the body, is frequently treated with iron supplements to increase the body's iron reserves and red blood cell formation. A genetic condition known as sickle cell anemia is typified by aberrant hemoglobin, which results in malformed red blood cells. Treatment options include hydroxyurea treatment, blood transfusions, and pain management. Low levels of red blood cell, white blood cell, and platelet counts result from aplastic anemia, which is caused by insufficient production of blood cells by the bone marrow. Hemolytic anemia, which results from the early breakdown of red blood cells, can be managed by treating the underlying condition, such as an infection or an autoimmune disease.

  • By Route of Administration

Based on the route of administration, the global anemia drugs market is categorized into oral and injectable. The oral category leads the global anemia drugs market with the largest revenue share in 2023. Oral drugs are administered orally, usually as liquids, tablets, or capsules.
Patients can self-administer medication at home with these formulations' convenience and simplicity of use, negating the need for medical assistance. Iron supplements for iron deficiency anemia and vitamin B12 supplements for pernicious anemia are common oral anemia medications. Using an injection, injectable drugs can be given intravenously (into a vein) or subcutaneously (under the skin).
Medication can be quickly and directly delivered into the bloodstream with injectable formulations, avoiding the digestive tract.


Global Anemia Drugs Overview by Region

The global anemia drugs market is categorized into North America, Europe, Asia-Pacific, and the Rest of the World. North America emerged as the leading region, capturing the largest market share in 2023. First, the area has a large spending on healthcare and a sophisticated infrastructure for healthcare, which makes diagnosis and treatment widely accessible. Effective remedies are in high demand due to the region's huge aging population, which makes them susceptible to anemia. Furthermore, a supportive regulatory framework and active research and development efforts support the release of novel anemia medications. Moreover, robust partnerships between pharmaceutical firms and academic institutions drive progress in the treatment of anemia, reinforcing North America's standing as a major player in the international market.

Throughout the forecast period, Asia-Pacific is anticipated to post a significant CAGR. Its rise is driven by multiple factors. First, there is a sizable patient pool because anemia is common in the area's big and aging population. Secondly, increased spending and better infrastructure for healthcare make diagnosis and treatment more accessible. Demand for novel therapeutics is also fueled by growing awareness of anemia and technological developments in medicine. Additionally, pharmaceutical companies and healthcare stakeholders work together to develop and commercialize innovative anemia medications, which promotes market expansion in the Asia-Pacific area.


Global Anemia Drugs Competitive Landscape

In the global anemia drugs market, a few major players exert significant market dominance and have established a strong regional presence. These leading companies remain committed to continuous research and development endeavors and actively engage in strategic growth initiatives, including product development, launches, joint ventures, and partnerships. By pursuing these strategies, these companies aim to strengthen their market position, expand their customer base, and capture a substantial share of the market.

Some of the prominent players in the global anemia drugs market include,

  • GlaxoSmithKline
  • Global Blood Therapeutics (GBT)
  • Bluebird Bio
  • GlycoMimetics
  • Mast Therapeutics
  • Fibrogen
  • Akebia Therapeutics
  • Bayer AG, and various others.


Global Anemia Drugs Recent Developments

  • In February 2023, The FDA in the United States approved GSK Plc's (GSK.L) novel tab medication as the first oral treatment for anemia brought on by chronic renal disease in adults receiving dialysis for a minimum of four months.  The medication Jesduvroq carries a boxed warning about an elevated risk of thrombotic vascular events, which can include blood clots in the legs, lungs, or dialysis access site, as well as mortality, heart attack, and stroke


Scope of the Global Anemia Drugs Report

Anemia Drugs Market Report Segmentation



By Anemia Type

  • Iron Deficiency Anemia
  • Sickle Cell Anemia
  • Aplastic Anemia
  • Hemolytic Anemia
  • Pernicious Anemia
  • Others

By Route of Administration

  • Oral
  • Injectable

By Geography

  • North America (USA, and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Russia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Customization Scope

  • Available upon request


  • Available upon request


Objectives of the Study

The objectives of the study are summarized in 5 stages. They are as mentioned below:

  • Global Anemia Drugs Market Size and Forecast: To identify and estimate the market size for the global anemia drugs market segmented by anemia type, by route of administration, region and by value (in U.S. dollars). Also, to understand the consumption/ demand created by consumers of anemia drugs between 2019 and 2032.
  • Market Landscape and Trends: To identify and infer the drivers, restraints, opportunities, and challenges for the global anemia drugs market
  • Market Influencing Factors: To find out the factors which are affecting the sales of anemia drugs among consumers
  • Impact of COVID-19: To identify and understand the various factors involved in the global anemia drugs market affected by the pandemic
  • Company Profiling:  To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company's past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.


Intended Audience

  • Healthcare Providers
  • Pharmaceutical Companies
  • Healthcare Institutions
  • Investors and Analysts
  • Regulatory Authorities

Research Methodology

Our research methodology has always been the key differentiating reason which sets us apart in comparison from the competing organizations in the industry. Our organization believes in consistency along with quality and establishing a new level with every new report we generate; our methods are acclaimed and the data/information inside the report is coveted. Our research methodology involves a combination of primary and secondary research methods. Data procurement is one of the most extensive stages in our research process. Our organization helps in assisting the clients to find the opportunities by examining the market across the globe coupled with providing economic statistics for each and every region.  The reports generated and published are based on primary & secondary research. In secondary research, we gather data for global Market through white papers, case studies, blogs, reference customers, news, articles, press releases, white papers, and research studies. We also have our paid data applications which includes hoovers, Bloomberg business week, Avention, and others.

Data Collection

Data collection is the process of gathering, measuring, and analyzing accurate and relevant data from a variety of sources to analyze market and forecast trends. Raw market data is obtained on a broad front. Data is continuously extracted and filtered to ensure only validated and authenticated sources are considered. Data is mined from a varied host of sources including secondary and primary sources.

Primary Research

After the secondary research process, we initiate the primary research phase in which we interact with companies operating within the market space. We interact with related industries to understand the factors that can drive or hamper a market. Exhaustive primary interviews are conducted. Various sources from both the supply and demand sides are interviewed to obtain qualitative and quantitative information for a report which includes suppliers, product providers, domain experts, CEOs, vice presidents, marketing & sales directors, Type & innovation directors, and related key executives from various key companies to ensure a holistic and unbiased picture of the market. 

Secondary Research

A secondary research process is conducted to identify and collect information useful for the extensive, technical, market-oriented, and comprehensive study of the market. Secondary sources include published market studies, competitive information, white papers, analyst reports, government agencies, industry and trade associations, media sources, chambers of commerce, newsletters, trade publications, magazines, Bloomberg BusinessWeek, Factiva, D&B, annual reports, company house documents, investor presentations, articles, journals, blogs, and SEC filings of companies, newspapers, and so on. We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

Top-Down Approach & Bottom-Up Approach

In the top – down approach, the Global Batteries for Solar Energy Storage Market was further divided into various segments on the basis of the percentage share of each segment. This approach helped in arriving at the market size of each segment globally. The segments market size was further broken down in the regional market size of each segment and sub-segments. The sub-segments were further broken down to country level market. The market size arrived using this approach was then crosschecked with the market size arrived by using bottom-up approach.

In the bottom-up approach, we arrived at the country market size by identifying the revenues and market shares of the key market players. The country market sizes then were added up to arrive at regional market size of the decorated apparel, which eventually added up to arrive at global market size.

This is one of the most reliable methods as the information is directly obtained from the key players in the market and is based on the primary interviews from the key opinion leaders associated with the firms considered in the research. Furthermore, the data obtained from the company sources and the primary respondents was validated through secondary sources including government publications and Bloomberg.

Market Analysis & size Estimation

Post the data mining stage, we gather our findings and analyze them, filtering out relevant insights. These are evaluated across research teams and industry experts. All this data is collected and evaluated by our analysts. The key players in the industry or markets are identified through extensive primary and secondary research. All percentage share splits, and breakdowns have been determined using secondary sources and verified through primary sources. The market size, in terms of value and volume, is determined through primary and secondary research processes, and forecasting models including the time series model, econometric model, judgmental forecasting model, the Delphi method, among Flywheel Energy Storage. Gathered information for market analysis, competitive landscape, growth trends, product development, and pricing trends is fed into the model and analyzed simultaneously.

Quality Checking & Final Review

The analysis done by the research team is further reviewed to check for the accuracy of the data provided to ensure the clients’ requirements. This approach provides essential checks and balances which facilitate the production of quality data. This Type of revision was done in two phases for the authenticity of the data and negligible errors in the report. After quality checking, the report is reviewed to look after the presentation, Type and to recheck if all the requirements of the clients were addressed.

Frequently Asked Questions

On the basis of Geography, the anemia drugs market is classified into North America, Europe, Asia Pacific, and the Rest of the world
According to anemia drugs market research, the market is expected to grow at a CAGR of ~9.4% over the coming years.
Asia-Pacific is expected to register the highest CAGR during 2024 - 2032
North America held the largest share in 2023
The major players operating in the global market include GlaxoSmithKline, Global Blood Therapeutics (GBT), Bluebird Bio, GlycoMimetics, Mast Therapeutics, Fibrogen, Akebia Therapeutics, Bayer AG, and various others.

Avail PDF Sample Reports